In addition to druggable pathways, characterizing SSVs in DLBCL cell lines also identified the key genes FCGR3A, FLT4, and CYP2B6, whose mutations would affect the drug response in the patients. The gene discussed is FLT4; the disease is diffuse large B-cell lymphoma.